Electronic product information (ePI)
Submitted by Anonymous (not verified) on 28 August 2026 - 10:00
Electronic product information (ePI)
PSUSA/00011041/202510
Submitted by Anonymous (not verified) on 28 August 2026 - 9:49
PSUSA/00011041/202510
How to pay fees and charges levied by EMA: Guidance to marketing authorisation holders and applicants
Submitted by Anonymous (not verified) on 28 August 2026 - 9:36
How to pay fees and charges levied by EMA: Guidance to marketing authorisation holders and applicants
How to pay
Submitted by Anonymous (not verified) on 28 August 2026 - 9:36
How to pay
SEPA Direct Debit B2B: Guidance for marketing authorisation holders and applicants
Submitted by Anonymous (not verified) on 28 August 2026 - 9:33
SEPA Direct Debit B2B: Guidance for marketing authorisation holders and applicants
Human medicines European public assessment report (EPAR): SomaKit TOC, edotreotide, Date of authorisation: 08/12/2016, Revision: 24, Status: Authorised
Submitted by Anonymous (not verified) on 28 August 2026 - 7:57
Human medicines European public assessment report (EPAR): SomaKit TOC, edotreotide, Date of authorisation: 08/12/2016, Revision: 24, Status: Authorised
Human medicines European public assessment report (EPAR): Vyndaqel, tafamidis, Date of authorisation: 16/11/2011, Revision: 32, Status: Authorised
Submitted by Anonymous (not verified) on 27 August 2026 - 16:30
Human medicines European public assessment report (EPAR): Vyndaqel, tafamidis, Date of authorisation: 16/11/2011, Revision: 32, Status: Authorised
Tackling antimicrobial resistance: Information for animal health practitioners
Submitted by Anonymous (not verified) on 27 August 2026 - 15:30
Tackling antimicrobial resistance: Information for animal health practitioners
Human medicines European public assessment report (EPAR): Bilprevda, denosumab, Date of authorisation: 17/09/2025, Revision: 4, Status: Authorised
Submitted by Anonymous (not verified) on 27 August 2026 - 15:00
Human medicines European public assessment report (EPAR): Bilprevda, denosumab, Date of authorisation: 17/09/2025, Revision: 4, Status: Authorised
Human medicines European public assessment report (EPAR): Hulio, adalimumab, Date of authorisation: 17/09/2018, Revision: 21, Status: Authorised
Submitted by Anonymous (not verified) on 27 August 2026 - 14:54
Human medicines European public assessment report (EPAR): Hulio, adalimumab, Date of authorisation: 17/09/2018, Revision: 21, Status: Authorised